Karyopharm Therapeutics Inc. (KPTI)

1,0200 -0,0800 (-7,27%) Börsenschluss: 04:00PM EDT

Karyopharm Therapeutics Inc.

85 Wells Avenue
Suite 210
Newton, MA 02459-3298
United States
617 658 0600
https://www.karyopharm.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 325

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Richard A. Paulson M.B.A.	President, CEO & Director	1,43M	N/A	1967
Mr. Michael P. Mason CPA, M.B.A.	Executive VP, CFO & Treasurer	712,68k	N/A	1975
Ms. Sohanya Cheng M.B.A.	Executive VP & Chief Commercial Officer	742,95k	N/A	1983
Mr. Stuart Poulton	Executive VP & Chief Development Officer	682,48k	N/A	N/A
Dr. Reshma Rangwala M.D., Ph.D.	Executive VP, Chief Medical Officer & Head of Research	777,32k	N/A	1978
Dr. Mansoor Raza Mirza M.D.	Clinical Consultant, Member of Scientific Advisory Board & Independent Director	150k	N/A	1961
Dr. Sharon Shacham M.B.A., Ph.D.	Co-Founder & Chairman of Scientific Advisory Board	1,4M	N/A	1970
Mr. Cameron Peters	Vice President of Finance, Assistant Treasurer & Principal Accounting Officer	N/A	N/A	1960
Ms. Elhan Webb C.F.A.	Senior Vice President of Investor Relations	N/A	N/A	N/A
Mr. Michael J. Mano J.D.	Senior VP, General Counsel & Secretary	625,08k	N/A	1977

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Corporate Governance

Karyopharm Therapeutics Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 8, Vorstand: 8, Shareholderrechte: 8, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.